Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO: VEGF Trap-Eye for Macular Edema Secondary to CRVO
NCT01012973Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2009
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of aflibercept in macular edema, sponsored by Bayer. Started Oct 2009; status: completed.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01012973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012973.